Second Sight Medical Products (NASDAQ: EYES) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it weigh in compared to its peers? We will compare Second Sight Medical Products to similar businesses based on the strength of its valuation, profitability, analyst recommendations, risk, earnings, dividends and institutional ownership.

Profitability

This table compares Second Sight Medical Products and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Second Sight Medical Products -565.12% -184.87% -137.77%
Second Sight Medical Products Competitors -101.23% -92.70% -30.32%

Institutional and Insider Ownership

12.7% of Second Sight Medical Products shares are owned by institutional investors. Comparatively, 54.9% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 50.9% of Second Sight Medical Products shares are owned by insiders. Comparatively, 11.9% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Second Sight Medical Products and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Second Sight Medical Products $3.98 million -$33.17 million -1.84
Second Sight Medical Products Competitors $1.67 billion $207.58 million 74.79

Second Sight Medical Products’ peers have higher revenue and earnings than Second Sight Medical Products. Second Sight Medical Products is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and target prices for Second Sight Medical Products and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Second Sight Medical Products 0 0 1 0 3.00
Second Sight Medical Products Competitors 109 728 1025 10 2.50

Second Sight Medical Products presently has a consensus target price of $5.00, indicating a potential upside of 306.50%. As a group, “Medical Devices & Implants” companies have a potential upside of 36.36%. Given Second Sight Medical Products’ stronger consensus rating and higher probable upside, analysts clearly believe Second Sight Medical Products is more favorable than its peers.

Summary

Second Sight Medical Products peers beat Second Sight Medical Products on 7 of the 11 factors compared.

About Second Sight Medical Products

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.

Receive News & Ratings for Second Sight Medical Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.